T2 Biosystems Announces Presentations at ASM Microbe 2017 Conference
24 May 2017 - 10:00PM
T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging
leader in the development of innovative diagnostic products to
improve patient health, today announced two Industry & Science
Showcases during the American Society for Microbiology (ASM)
Microbe 2017 Conference in New Orleans, LA., June 1-5.
Additionally, there will be several Sessions and Poster
Presentations focused on the positive impact of the T2 Magnetic
Resonance (T2MR®) technology by T2 Biosystems and its customers and
collaborators. A schedule of all relevant presentations is as
follows:
COMPANY INDUSTRY & SCIENCE
SHOWCASE: “Application of Rapid, Blood
Culture-Free Diagnostics in the Emergency Department: Improving the
Signal to Noise Ratio”Presenters: Dr. Mitchell J.
Cohen, M.D., Director of Surgery, Denver Health and the University
of Colorado School of Medicine, Denver,
COOverview: This symposium offers expert guidance
on the application of T2MR technology in the Emergency Department
setting. Currently in FDA clinical trials, the T2Bacteria Panel
identifies bloodstream infection pathogens commonly isolated from
patients throughout the hospital, and most often presenting in the
Emergency Department. Learn how T2Bacteria may help improve your
patient triage, case management and admission
processes.Time: June 2, 1:30-2:15
p.m.Location: Theater B
COMPANY INDUSTRY & SCIENCE
SHOWCASE: “Managing Sepsis in the Golden
Hour: Controlling Costs and Improving Patient Care through
Diagnostic Testing”Presenters: Dr. Thomas Kirn,
MD, PHD, Rutgers Robert Wood Johnson Medical School, New Brunswick,
NJ, and Dr. Jonathan D. Edwards, Pharm.D., BCPS (AQ-ID), BCGP,
Huntsville Hospital, Huntsville, ALOverview: This
symposium will provide a forum for peer-to-peer learning on the
proven impact of T2MR technology. This session will review the
positive patient care impact and economic benefits realized by
using the only FDA-cleared, direct-from-whole-blood assay for the
identification of sepsis-causing pathogens, while also discussing
products in development that may have a similar impact on
healthcare. Time: June 4, 12:30 - 1:15
p.m.Location: Theater B
SESSION: “Debates in Medical
Mycology”Debate 2: “Management of Invasive
Candidiasis - T2 is the New Standard in Managing IC”Session
Number: #116Presenter: Samuel L. Aitken,
PharmD, BCPS, The University of Texas MD Anderson Cancer Ctr.,
Houston, TXTime: June 2, 3:00-5:30 p.m. (Talk 5
scheduled to begin at 4:00 p.m.)
LATE BREAKER POSTER SESSION: “Assessing High
Sensitivity Direct from Blood Pathogen Detection”Poster
Number: #056aPresented by: T2
BiosystemsPresenting Authors: H. S. Lapp, R. P.
Shivers; T2 BiosystemsTime: June 2, 12:45-2:45
p.m.Location: Exhibit Hall D, Exhibit and Poster
Hall
POSTER PRESENTATION: “Clinical Urine Specimens
as a Sample Matrix for T2 Magnetic Resonance
Technology”Poster Number: #454Presented
by: Indiana University School of
MedicinePresenting Author: T. Kieffer, Dept.
of Pathology and Lab. Med., Indiana Univ. Sch. of
Med.Time: June 4, 12:15-2:15
p.m.Location: Exhibit Hall D, Exhibit and Poster
Hall
POSTER PRESENTATION: “T2
Magnetic Resonance Technology for the Diagnosis of Candidemia in
Low Volume Whole Blood Specimens”Poster Number:
#464Presented by: Indiana University School
of MedicinePresenting Author: T. Kieffer, Dept. of
Pathology and Lab. Med., Indiana Univ. Sch. of
Med.Time: June 4, 12:15-2:15
p.m.Location: Exhibit Hall D, Exhibit and Poster
Hall
POSTER PRESENTATION:
“Diagnosis of Fungal Peritonitis Caused by Candida spp. Using T2
Magnetic Resonance Technology on Dialysate Matrix”Poster
Number: #473Presented by: Indiana
University School of MedicinePresenting Author: T.
Kieffer, Dept. of Pathology and Lab. Med., Indiana Univ. Sch. of
Med.Time: June 4, 12:15-2:15
p.m.Location: Exhibit Hall D, Exhibit and Poster
Hall
About T2 Biosystems T2 Biosystems is
focused on developing innovative diagnostic products to improve
patient health. With the FDA-cleared T2Dx® Instrument and
T2Candida® Panel targeting sepsis, a life-threatening infection,
and a range of additional products in development, T2 Biosystems is
an emerging leader in the field of in vitro diagnostics. The
Company is utilizing its proprietary T2MR technology to develop a
broad set of applications aimed at lowering mortality rates,
improving patient outcomes and reducing the cost of healthcare by
helping medical professionals make targeted treatment decisions
earlier. T2MR enables the fast and sensitive detection of
pathogens, biomarkers and other abnormalities in a variety of
patient sample types, including whole blood. For more information,
please visit www.t2biosystems.com.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements. These forward-looking statements are based on
management's current expectations. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements, including, but not
limited to, the performance of the Company's diagnostic products
and the ability to bring such products to market. These and other
important factors could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. For more information on risk factors for T2
Biosystems, Inc.’s business, please refer to the Company’s Annual
Report on Form 10-K, filed with the Securities and Exchange
Commission on March 15, 2017, under the heading “Risk
Factors,” and other filings the Company makes with
the Securities and Exchange Commission from time to time.
Any such forward-looking statements represent management's
estimates as of the date of this press release. While the Company
may elect to update such forward-looking statements at some point
in the future, it disclaims any obligation to do so, even if
subsequent events cause its views to change. These forward-looking
statements should not be relied upon as representing the Company's
views as of any date subsequent to the date of this press
release.
Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
ddeptula@t2biosystems.com
603-553-5803
Media Contact:
Matthew McKillip, T2 Biosystems
mmckillip@t2biosystems.com
518-577-3466
Investor Contact:
Tucker Elcock, Teneo Strategy
Tucker.Elcock@teneostrategy.com
212-886-9319
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2024 to May 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From May 2023 to May 2024